Overview

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2004-12-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17

Phase:

Phase 2

Details

Lead Sponsor:

Shire

Treatments:

Amphetamine
Guanfacine
Methylphenidate